Castle Biosciences (CSTL) Cost of Revenue (2018 - 2026)

Castle Biosciences has reported Cost of Revenue for 9 years, with the latest figure at $23.7 million in Q2 2026.

• Quarterly Cost of Revenue rose 34.46% year-over-year to $23.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $81.3 million (up 23.48% YoY) and the FY2025 annual result came in at $71.0 million, up 17.98% from the prior year.
• Cost of Revenue grew to $23.7 million in Q2 2026 per CSTL's latest filing, from $20.5 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $23.7 million in Q2 2026 and troughed at $5.9 million in Q1 2022.
• A 5-year average of $14.0 million and a median of $14.2 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue jumped 107.9% in 2022, then rose 13.17% in 2025.
• Over 5 years, Cost of Revenue stood at $9.5 million in 2022, then jumped by 30.49% to $12.4 million in 2023, then soared by 30.27% to $16.2 million in 2024, then climbed by 13.17% to $18.3 million in 2025, then rose by 29.4% to $23.7 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $23.7 million, $20.5 million, and $18.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.